Leishmania IgG Antibody (KALA-AZAR)

Leishmania IgG Antibody Test (Kala-Azar)

The Leishmania IgG Antibody Test (Kala-Azar) is a laboratory blood test used to detect Immunoglobulin G (IgG) antibodies against Leishmania parasites, the organisms responsible for visceral leishmaniasis (VL), commonly known as Kala-Azar. This test helps support the diagnosis of visceral leishmaniasis in patients with compatible symptoms and relevant exposure history.

Visceral leishmaniasis is a serious parasitic disease caused primarily by Leishmania donovani and Leishmania infantum. The parasite is transmitted through the bite of infected female phlebotomine sandflies. The disease is endemic in several countries, including parts of India, Bangladesh, Nepal, East Africa, South America, and the Mediterranean region.

Without appropriate treatment, visceral leishmaniasis can be life-threatening. Common symptoms include:

• Persistent or prolonged fever
• Significant weight loss
• Enlarged spleen (splenomegaly)
• Enlarged liver (hepatomegaly)
• Fatigue and weakness
• Anemia
• Low white blood cell count (leukopenia)
• Low platelet count (thrombocytopenia)

During infection, the immune system produces IgG antibodies against Leishmania parasites. Detection of these antibodies strongly supports the diagnosis of visceral leishmaniasis in patients from endemic areas with compatible clinical findings. However, IgG antibodies may remain detectable for months or years after successful treatment, so a positive result does not necessarily indicate active infection.

The Leishmania IgG Antibody Test is usually interpreted alongside clinical findings, complete blood count (CBC), imaging studies, travel or residence history, and, when indicated, confirmatory tests such as PCR or parasite identification from bone marrow, spleen, or lymph node aspirates.

Early diagnosis is essential because prompt treatment greatly improves outcomes and reduces complications.

Benefits of the Test

• Detects IgG antibodies against Leishmania parasites.
• Supports diagnosis of visceral leishmaniasis (Kala-Azar).
• Assists in evaluating prolonged fever of unknown origin.
• Requires only a simple blood sample.
• Useful in endemic regions.
• Supports early diagnosis and treatment planning.
• Complements molecular and parasitological investigations.
• Reliable serological screening method.

Why Doctors Recommend This Test

Doctors recommend the Leishmania IgG Antibody Test for patients with persistent fever, enlarged spleen, anemia, pancytopenia, weight loss, or suspected visceral leishmaniasis, particularly those living in or returning from endemic regions.

Preparation Before the Test

No special preparation is required.

You may eat and drink normally unless instructed otherwise by your healthcare provider. Inform your doctor about recent travel, residence in endemic areas, previous Leishmania infection, or treatment history. A blood sample is collected from a vein for laboratory analysis.

Normal Reporting Time

Typically: 2–5 Working Days

Reporting time may vary depending on laboratory methodology.

Who Should Take This Test?

This test may be recommended for:

• Individuals with prolonged unexplained fever.
• Patients with enlarged spleen or liver.
• Individuals with anemia or pancytopenia.
• People living in or returning from Kala-Azar endemic regions.
• Patients with suspected visceral leishmaniasis.
• Immunocompromised individuals with compatible symptoms.
• Individuals referred by infectious disease specialists.
• Patients undergoing evaluation for tropical diseases.
• Individuals participating in public health investigations.
• Anyone advised by their healthcare provider.